CSL reports changes in director's share interests, rights cessation

CSL Limited announced the cessation of 110,017 unquoted conditional rights (ASX: CSLAL) on September 1, 2025. These rights lapsed because the conditions for conversion were not met or became incapable of being satisfied. This figure includes 98,181 rights that lapsed due to unfulfilled performance conditions and an additional 11,836 rights due to the processing of August 2025 leavers. Following this cessation, the total number of unquoted CSLAL rights on issue is 1,197,787. The company's quoted ordinary fully paid shares (ASX: CSL) remain at 485,000,909.

In a separate update, CSL also reported the cessation of 340 unquoted rights (ASX: CSLAL) on September 1, 2205, which were subject to cash settlement under the long-term incentive plan. The company paid a consideration of AUD 215.07 per security for these cessations. Following this adjustment, the total number of unquoted CSLAL rights on issue stands at 1,307,464.

Further disclosures show changes in director Dr. Paul McKenzie’s interests, effective September 1, 2025. Dr. McKenzie exercised 8,101 performance share units, which converted into ordinary shares. Additionally, 13,261 unvested performance share units lapsed as performance hurdles were not met. To satisfy withholding tax obligations, 3,699 ordinary shares were sold in an on-market trade, generating AUD 772,402.39. After these changes, Dr. McKenzie indirectly holds 82,160 performance share units and 27,354 ordinary shares through Solium Nominees (Australia) Pty Ltd as custodian for the CSL Limited Performance Rights Plan.